Key facts
- Shanghai Bao Pharmaceuticals’s last known valuation is $1.1B (Dec 2025).
- It has raised $262.9M; the latest was IPO ($128.5M) in Dec 2025.
- Notable investors include Guotai Junan Innovation Investment, Anhui Anke Biotechnology (Group) Company, Derivatives China.
- Status: Publicly Held.
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Shanghai Bao Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Shanghai Bao Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Shanghai Bao Pharmaceuticals
Provider of clinical trial services, drug development and drug manufacturing services designed to create recombinant protein drugs and recombinant antibodies. The company's services integrate drug research and development and production to produce raw liquid like mammalian cell expression systems, large intestine and yeast expression systems, water injections and freeze-dried powder injections, enabling the biopharmaceutical industry to commercialize its protein and antibody drug production lines.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2019
- Website
- baopharma.com/
- Ownership
- Publicly Held
Shanghai Bao Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Shanghai Bao Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Shanghai Bao Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.